You are here
Wednesday, December 14, 2011
NIH-supported study finds no benefit for a liberal transfusion strategy after hip-fracture surgery
A liberal strategy for providing red blood cell transfusions following hip-fracture surgery to patients at risk for cardiovascular disease neither lowered their post-surgical risk of death nor improved their recovery rates when compared to a restrictive transfusion strategy, according to new research supported by the National Institutes of Health.
The study compared a liberal and a restrictive transfusion therapy based on patients' hemoglobin levels. It found no significant differences in survival or recovery rates 60 days after surgery. The findings will appear online Dec. 14 in the New England Journal of Medicine.
"Blood transfusions can save lives, but they are not without risks," said Susan B. Shurin, M.D., acting director of the National Heart, Lung, and Blood Institute, the institute within NIH that supported the research. "Knowing when to perform blood transfusions may help patients avoid unnecessary medical procedures, and their associated risks, and help conserve our limited blood supply."
The study involved 2,016 patients with an average age of 82 who underwent hip fracture surgery. All study participants were at high risk for cardiovascular disease and had hemoglobin levels below 10 grams per deciliter after surgery. Hemoglobin, an oxygen-transporting protein in the blood, is normally present at a level of about 12 grams per deciliter or higher in healthy older men and women. When the hemoglobin level falls below 8 grams per deciliter, people can experience anemia symptoms and an increased risk of serious cardiovascular events, such as heart failure, and death.
Participants in the liberal therapy group were given transfusions if their hemoglobin levels fell below 10 grams per deciliter. Participants in the restrictive therapy group were given transfusions if their hemoglobin levels fell below 8 grams per deciliter or if they displayed symptoms of anemia and a physician determined transfusions were warranted. Emergency transfusions were also given to any participant as needed if there was bleeding. About 40 percent of patients in the restrictive therapy group received red blood cell transfusions compared to nearly everyone in the liberal therapy group.
After 60 days of follow-up, mortality rates were not significantly different between the two groups (7.6 percent in the liberal therapy group and 6.6 percent in the restrictive therapy group) and equal numbers of participants in both groups (28 percent) were unable to walk 10 feet without human aid, the measure used to gauge recovery.
Jeffrey L. Carson, M.D., with the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, in New Brunswick, led the research effort.
To arrange an interview with an NHLBI spokesperson, please contact the NHLBI Communications Office at (301) 496-4236 or email@example.com.
Read more about the trial at: http://clinicaltrials.gov/ct2/show/NCT00071032?term=carson+transfusion&rank=3
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at www.nhlbi.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®